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Thoracoscopic Left Cardiac Sympathetic Denervation for a Patient 
with Catecholaminergic Polymorphic Ventricular Tachycardia and 
Recurrent Implantable Cardioverter-Defibrillator Shocks
Woo-Sik Yu, M.D.1, Tae-Hoon Kim, M.D.2, Jee won Suh, M.D.1, Seunghwan Song, M.D.1, 
Chang Young Lee, M.D.1, Boyoung Joung, M.D., Ph.D.2
A patient presented with loss of consciousness and conversion. During an exercise test, catecholaminergic poly-
morphic ventricular tachycardia (CPVT) resulted in cardiac arrest. He started taking medication (a beta-blocker and 
flecainide) and an implantable cardioverter defibrillator (ICD) was inserted, but the ventricular tachycardia did not 
resolve. Left cardiac sympathetic denervation (LCSD) was then performed under general anesthesia, and the patient 
was discharged on the second postoperative day without complications. One month after the operation, no shock 
had been administered by the ICD, and an exercise stress test did not induce ventricular tachycardia. Although be-
ta-blockers are the gold standard of therapy in patients with CPVT, thoracoscopic LCSD is safe and can be an 
effective alternative treatment option for patients with intractable CPVT.
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CASE REPORT
An 8-year-old patient presented with loss of consciousness 
and conversion. He had an unremarkable medical history and 
no family history of epilepsy or sudden cardiac death. Brain 
magnetic resonance imaging, echocardiography (ECG), and 
24-hour Holter ECG monitoring revealed no abnormal 
findings. An electroencephalogram led us to suspect a partial 
seizure disorder originating from the frontal area. Subsequently, 
the patient experienced recurrent syncopal episodes despite 
taking antiepileptic medication for four years and the absence 
of epileptic discharges on follow-up electroencephalograms. 
At 12 years of age, his cardiac function was re-evaluated be-
cause he reported chest discomfort before syncopal episodes. 
Echocardiography, 24-hour Holter ECG monitoring, and 
head-up tilt testing revealed normal findings. However, poly-
morphic ventricular tachycardia was induced during an ex-
ercise stress test (Fig. 1). These findings were consistent with 
catecholaminergic polymorphic ventricular tachycardia (CPVT), 
and the patient was started on a beta-blocker. At the age of 
15 years, while on the beta-blocker therapy (metoprolol, 200 
mg/day), the patient went into cardiac arrest with initial ven-
tricular fibrillation and underwent defibrillation with an auto-
mated external defibrillator. An implantable cardioverter de-
fibrillator (ICD) was inserted, and flecainide was added to his 
medication regimen. However, after ICD insertion, the patient 
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Fig. 1. The results of exercise 
stress tests differed significantly (A) 
before and (B) after left cardiac sym-
pathetic denervation. (A) Bidirectional 
polymorphic ventricular tachycardia 
consistent with typical catecholamin-
ergic polymorphic ventricular tachy-
cardia was induced during the pre-
operative exercise stress test. (B) 
Occasional premature ventricular beats 
without ventricular tachycardia were 
recorded during the postoperative ex-
ercise stress test.
developed recurrent hemodynamically stable ventricular tachy-
cardia (VT), and six shocks were delivered over the course of 
six months. These episodes of VT were not terminated by 
shocks from the ICD, but instead persisted for some time, 
eventually terminating spontaneously (Fig. 2). He was re-
ferred to the general thoracic department for left cardiac sym-
pathetic denervation (LCSD). The operation was performed 
under general anesthesia. Intubation was carried out using a 
dual-lumen endotracheal tube for one-lung ventilation. The 
patient was placed in the right lateral decubitus position. A 
10-mm 30o thoracoscope was used. A 12-mm trocar was in-
serted on the sixth midaxillary line for the camera, and two 
5-mm trocars were inserted on the third and the fifth anterior 
axillary lines for the endoscopic instruments. The sympathetic 
chain was identified from T1 to T5 and resected, including 
the lateral nerve branches, using a harmonic scalpel with 
sparing of the stellate ganglion (Fig. 3). A 20-Fr chest tube 
was placed in the left pleural cavity at the end of the oper-
ation and was removed on the first postoperative day. The 
patient was discharged on the second postoperative day with-
out complications and maintained on metoprolol (300 
mg/day) and flecainide (100 mg/day). As of one month after 
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Fig. 2. The recurrent hemodynami-
cally stable VT that was observed 
preoperatively could not be termi-
nated by ICD shocks, and instead 
eventually terminated spontaneously. 
VT, ventricular tachycardia; ICD, im-
plantable cardioverter defibrillator.
Fig. 3. Intraoperative findings during 
left cardiac sympathetic denervation 
in a patient with catecholaminergic 
polymorphic ventricular tachycardia. 
(A) Thoracoscopic port placement. (B−
D) Intraoperative findings. The sym-
pathetic chain was identified from T1 
to T5 and resected (including the 
lateral nerve branches) using a har-
monic scalpel, while sparing the stel-
late ganglion (arrow).
the operation, no shocks had been administered by the ICD, 
and an exercise stress test did not induce VT (Fig. 1).
DISCUSSION
CPVT was first described in 1975 [1], and is characterized 
by bidirectional or polymorphic ventricular tachycardia in-
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duced by increased sympathetic activity secondary to physical 
exercise or emotional stress [2]. Genetic studies in the past dec-
ade have revealed mutations in two genes (RYR2, CASQ2) [3] 
that are known to be associated with abnormal intracellular 
calcium handling and cause adrenergically mediated poly-
morphic ventricular tachyarrhythmias by delayed after-
depolarizations and triggered activity [4].
CPVT presents clinically with syncope, aborted cardiac ar-
rest, or sudden cardiac death, all of which are triggered by 
physical or emotional stress. Moreover, symptoms often de-
velop at a young age. In some cases, sudden death is the first 
manifestation [5]. Therefore, the accurate and early diagnosis 
of CPVT is critical for achieving the best possible clinical re-
sults in these patients. Reproducibility of the typical ar-
rhythmia by provocative testing, such as an exercise stress 
test or an isoproterenol infusion test, is important in establish-
ing the diagnosis [5]. However, CPVT-related syncopal epi-
sodes may include seizures involving urinary or fecal incon-
tinence, and usually present with normal ECG findings. 
Therefore, the average delay in diagnosis has been reported 
to be as high as 2.0±0.8 years after the manifestation of the 
first symptoms [6]. Our patient’s condition was initially mis-
diagnosed as epilepsy, and antiepileptic medication was ad-
ministered for four years, which resulted in a delayed diag-
nosis of CPVT.
Beta-blockers are the first-line therapy for CPVT, and they 
are known to provide most patients with sufficient protection. 
Since fatal ventricular storms can be initiated by shocks from 
an ICD that trigger subsequent catecholamine release [7], 
ICD placement should only be considered in patients who 
have been resuscitated after cardiac arrest and who have ex-
perienced recurring syncope or sustained VT despite be-
ta-blocker therapy [8]. Other pharmacologic treatments 
(sodium channel blockers, amiodarone, verapamil) have been 
shown to have an additive benefit in combination with be-
ta-blockers [5]. LCSD can be considered when ventricular ar-
rhythmias remain uncontrolled by beta-blockers and other ad-
ditive drug therapies. After Wilde et al. [2] first reported that 
LCSD is an effective therapy for CPVT, several other re-
searchers have confirmed that LCSD is highly effective and 
safe in severely affected CPVT patients [9]. Moreover, 
Hofferberth et al. [10] presented the results of thoracoscopic 
LCSD in 24 patients with life-threatening ventricular ar-
rhythmias, including nine patients with CPVT. In that study, 
16 of the 22 patients who underwent long-term follow-up ex-
perienced a marked reduction in arrhythmic events, and 12 
patients were completely free of arrhythmia. Moreover, no 
major complications and only three minor complications (two 
cases of pneumothorax and one case of Harlequin syndrome) 
were reported. The stellate ganglion was saved in all but one 
patient. Horner’s syndrome was not reported in any patients.
Schwartz [11] recently reviewed the experimental evidence 
pertaining to LCSD effectiveness. The author had previously 
reported that left stellectomy in dogs, which is the equivalent 
of LCSD in humans, raised the ventricular fibrillation thresh-
old, whereas right stellectomy lowered the ventricular fi-
brillation threshold. Other studies have reported the following 
findings: (1) left ventricular contractility is not reduced after 
left stellectomy; (2) no evidence indicates that LCSD induces 
post-denervation supersensitivity; (3) left stellectomy increases 
reactive hyperemia via the coronary artery; (4) after LCSD, 
the heart rate increases more than usual; and (5) LCSD in-
creases the activity of the cardiac vagal efferent nerve. 
Clinical evidence has indicated that LCSD may have a role 
in treating patients with channelopathies such as long QT 
syndrome, previous myocardial infarction, and CPVT [11].
In summary, CPVT is a genetic disorder involving intra-
cellular calcium handling that leads to adrenergically-mediated 
life threatening ventricular tachyarrhythmias. Although be-
ta-blockers are the gold standard of therapy in patients with 
CPVT, thoracoscopic LCSD is safe and can be an effective 
alternative treatment option. LCSD is a particularly important 
option for patients for whom beta-blockers are contraindicated 
and in patients who experience recurrent ICD shocks despite 
optimal treatment with medication.
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